Prelude Therapeutics secures $60M from Incyte option deal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Prelude Therapeutics secures $60M from Incyte option deal

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

November 4, 2025 7:01 AM EST

Incyte secures an exclusive option to acquire Preludes mutant selective JAK2V617F JH2 inhibitor program

Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs)

Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sales

Prelude will continue to develop all JAK2V617F program assets during the option period; if optioned, Incyte... More